CRISPR Therapeutics AG annual cash and equivalents
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
CRISPR Therapeutics AG Cash & Equivalents Growth & History (CRSP)
CRISPR Therapeutics AG's cash and equivalents was $347.6M for fiscal 2025.
View full CRISPR Therapeutics AG company overviewCRISPR Therapeutics AG annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $347.6M | $49.3M | +16.53% |
| 2024 | 2024-12-31 | $298.3M | −$91.2M | −23.42% |
| 2023 | 2023-12-31 | $389.5M | $177.6M | +83.82% |
| 2022 | 2022-12-31 | $211.9M | −$711.1M | −77.04% |
| 2021 | 2021-12-31 | $923.0M | −$245.6M | −21.02% |
| 2020 | 2020-12-31 | $1.17B | $224.8M | +23.82% |
| 2019 | 2019-12-31 | $943.8M | $487.1M | +106.67% |
| 2018 | 2018-12-31 | $456.6M | $216.9M | +90.46% |
| 2017 | 2017-12-31 | $239.8M | −$75.8M | −24.01% |
| 2016 | 2016-12-31 | $315.5M | $159.6M | +102.31% |
| 2015 | 2015-12-31 | $156.0M | $155.0M | +16403.81% |
| 2014 | 2014-12-31 | $945,000 | — | — |
CRISPR Therapeutics AG quarterly cash and equivalents
Q4.15
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $291.3M | $97.7M | +50.47% |
| Q1 2026 | 2026-03-31 | $423.3M | $188.1M | +79.99% |
| Q4 2025 | 2025-12-31 | $347.6M | $49.3M | +16.53% |
| Q3 2025 | 2025-09-30 | $286.5M | $60.8M | +26.95% |
| Q2 2025 | 2025-06-30 | $193.6M | −$290.9M | −60.04% |
| Q1 2025 | 2025-03-31 | $235.2M | −$472.2M | −66.76% |
| Q4 2024 | 2024-12-31 | $298.3M | −$91.2M | −23.42% |
| Q3 2024 | 2024-09-30 | $225.7M | −$302.1M | −57.24% |
| Q2 2024 | 2024-06-30 | $484.5M | $39.7M | +8.92% |
| Q1 2024 | 2024-03-31 | $707.4M | $363.0M | +105.40% |
| Q4 2023 | 2023-12-31 | $389.5M | $177.6M | +83.82% |
| Q3 2023 | 2023-09-30 | $527.8M | $33.6M | +6.80% |
| Q2 2023 | 2023-06-30 | $444.8M | −$52.1M | −10.48% |
| Q1 2023 | 2023-03-31 | $344.4M | −$339.5M | −49.64% |
| Q4 2022 | 2022-12-31 | $211.9M | −$711.1M | −77.04% |
| Q3 2022 | 2022-09-30 | $494.2M | −$517.4M | −51.15% |
| Q2 2022 | 2022-06-30 | $496.9M | −$1.15B | −69.82% |
| Q1 2022 | 2022-03-31 | $683.9M | −$442.2M | −39.27% |
| Q4 2021 | 2021-12-31 | $923.0M | −$245.6M | −21.02% |
| Q3 2021 | 2021-09-30 | $1.01B | −$29.9M | −2.87% |
| Q2 2021 | 2021-06-30 | $1.65B | $701.6M | +74.24% |
| Q1 2021 | 2021-03-31 | $1.13B | $236.3M | +26.56% |
| Q4 2020 | 2020-12-31 | $1.17B | $224.8M | +23.82% |
| Q3 2020 | 2020-09-30 | $1.04B | $411.7M | +65.38% |
| Q2 2020 | 2020-06-30 | $945.1M | $517.2M | +120.87% |
| Q1 2020 | 2020-03-31 | $889.7M | $452.2M | +103.34% |
| Q4 2019 | 2019-12-31 | $943.8M | $487.1M | +106.67% |
| Q3 2019 | 2019-09-30 | $629.7M | $142.4M | +29.23% |
| Q2 2019 | 2019-06-30 | $427.9M | $108.1M | +33.82% |
| Q1 2019 | 2019-03-31 | $437.5M | $95.8M | +28.03% |
| Q4 2018 | 2018-12-31 | $456.6M | $216.9M | +90.46% |
| Q3 2018 | 2018-09-30 | $487.3M | $233.8M | +92.21% |
| Q2 2018 | 2018-06-30 | $319.7M | $47.5M | +17.44% |
| Q1 2018 | 2018-03-31 | $341.8M | $52.9M | +18.31% |
| Q4 2017 | 2017-12-31 | $239.8M | −$75.8M | −24.01% |
| Q3 2017 | 2017-09-30 | $253.5M | $24.9M | +10.89% |
| Q2 2017 | 2017-06-30 | $272.3M | — | — |
| Q1 2017 | 2017-03-31 | $288.9M | — | — |
| Q4 2016 | 2016-12-31 | $315.5M | $159.6M | +102.31% |
| Q3 2016 | 2016-09-30 | $228.6M | — | — |
| Q4 2015 | 2015-12-31 | $156.0M | — | — |
CRISPR Therapeutics AG cash and equivalents trends
Over the last five fiscal years, CRISPR Therapeutics AG's cash and equivalents decreased from $1.17B to $347.6M, a change of −$821.1M. The latest reported quarter, Q2 2026, shows $291.3M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CRISPR Therapeutics AG source filings ↗